```html

Zollinger‑Ellison Syndrome (MEN‑1 with Pancreatic Neuroendocrine Tumors)

Overview

Zollinger‑Ellison syndrome (ZES) is a rare disorder characterized by gastrin‑producing tumors (gastrinomas) that cause excessive stomach acid secretion. When ZES occurs as part of multiple endocrine neoplasia type 1 (MEN‑1), patients often develop additional pancreatic neuroendocrine tumors (PNETs) and endocrine lesions of the parathyroid and pituitary glands.

• Prevalence: Isolated ZES occurs in about 1 – 3 per million people. MEN‑1 affects roughly 1 in 30,000–40,000 individuals, and up to 30 % of MEN‑1 patients develop ZES.<sup>1</sup>
• Typical age of onset: Gastrinomas present most often between ages 30–50; MEN‑1 manifestations can begin in the teens to early 30s.
• Gender: Slight male predominance for sporadic gastrinomas; MEN‑1 affects both sexes equally.

Symptoms

Symptoms arise from two main mechanisms: (1) hyperacidic gastric environment and (2) mass effect of the tumor(s). The clinical picture can be variable, especially when multiple endocrine tumors are present.

Gastric‑acid–related symptoms

• Peptic ulcer disease – recurrent or multiple ulcers, often beyond the duodenum (e.g., jejunal ulcers).
• Abdominal pain – burning or gnawing pain, typically worsened by meals.
• Diarrhea – watery, sometimes greasy stools due to acid inactivation of pancreatic enzymes.
• Heartburn / gastro‑esophageal reflux disease (GERD).
• Nausea and vomiting – may be chronic or post‑prandial.
• Weight loss – secondary to malabsorption and decreased intake.

Symptoms related to pancreatic neuroendocrine tumors (PNETs)

• Abdominal mass or fullness – palpable or felt as a vague pressure.
• Flushing, wheezing, or hypoglycemia – if the PNET secretes hormones such as insulin or vasoactive intestinal peptide (VIP).
• Jaundice – when a tumor compresses the common bile duct.

Other MEN‑1 manifestations

• Primary hyperparathyroidism – kidney stones, bone pain, fatigue.
• Pituitary adenoma – headaches, visual field defects, hormonal imbalances (e.g., prolactin excess).

Causes and Risk Factors

Genetic basis

ZES associated with MEN‑1 is caused by germline mutations in the MEN1 gene located on chromosome 11q13. This gene encodes the tumor suppressor protein menin. Loss‑of‑function mutations lead to uncontrolled cell growth in endocrine tissues.

Risk factors

• Family history of MEN‑1 – 95 % of cases are inherited in an autosomal‑dominant pattern.
• Known MEN1 mutation – carriers have a 50 % chance of passing the mutation to each child.
• Environmental factors – smoking and chronic H. pylori infection can worsen ulcer disease but do not cause gastrinomas.

Who is at risk?

Anyone with a confirmed MEN1 mutation, or with a first‑degree relative diagnosed with MEN‑1, should undergo regular screening. Sporadic gastrinomas (not linked to MEN‑1) are more common in individuals without a known genetic predisposition.

Diagnosis

Because symptoms overlap with common gastrointestinal conditions, a high index of suspicion is essential, especially in patients with a known MEN‑1 mutation.

Biochemical testing

• Fasting serum gastrin – levels > 1000 pg/mL are highly suggestive; however, values > 150 pg/mL with gastric pH < 2 strengthen the diagnosis.
• Secretin stimulation test – an increase in gastrin > 120 pg/mL after IV secretin is diagnostic for ZES.
• Chromogranin A – elevated in most neuroendocrine tumors, useful for monitoring.
• Calcium, PTH, and vitamin D – to assess concurrent hyperparathyroidism.

Imaging studies

• Somatostatin receptor scintigraphy (SRS) / Ga‑68 DOTATATE PET‑CT – most sensitive for locating gastrinomas and other PNETs.
• Endoscopic ultrasound (EUS) – excellent for detecting small pancreatic lesions (< 2 cm).
• CT or MRI abdomen – for anatomic detail, especially when evaluating liver metastases.
• Selective arterial secretagogue injection (SASI) test – rarely used now, but can localize lesions when non‑invasive imaging is inconclusive.

Pathology

If surgical resection is performed, the tumor is examined for size, mitotic rate, Ki‑67 index, and evidence of invasion. These factors guide staging and prognosis (ENETS/AJCC classification).

Treatment Options

Management combines acid suppression, surgical control of tumor burden, and long‑term surveillance.

Medical Therapy

• Proton pump inhibitors (PPIs) – high‑dose omeprazole, esomeprazole, or pantoprazole are first‑line. Doses often exceed standard ulcer doses (e.g., omeprazole 60–120 mg/day) and must be titrated to maintain gastric pH > 4.
• H2‑receptor antagonists – can be added if PPIs alone are insufficient.
• Somatostatin analogues (octreotide, lanreotide) – inhibit gastrin secretion and may shrink small neuroendocrine tumors. Particularly useful in metastatic disease.
• Interferon‑α or targeted agents (everolimus, sunitinib) – for progressive metastatic PNETs refractory to SSA.
• Management of MEN‑1‑related hyperparathyroidism – cinacalcet or surgical parathyroidectomy.

Surgical Options

• Localized gastrinoma – enucleation or distal pancreatectomy with regional lymph node dissection.
• Multiple or duodenal gastrinomas (common in MEN‑1) – duodenotomy with systematic excision of lesions; pancreaticoduodenectomy (Whipple) is reserved for extensive disease.
• Metastatic disease – hepatic resection, radiofrequency ablation, or liver-directed therapies (e.g., ^90Y‑90 microspheres) when feasible.
• Prophylactic surgery – not routinely recommended; decision based on tumor size (> 2 cm), growth rate, and patient’s overall health.

Lifestyle & Supportive Measures

• Small, frequent meals; avoid foods that stimulate acid (caffeine, alcohol, spicy foods).
• Stay hydrated; oral rehydration solutions may be needed for chronic diarrhea.
• Calcium and vitamin D supplementation if hyperparathyroidism is present.
• Psychosocial support – counseling or support groups for hereditary cancer syndromes.

Living with Zollinger‑Ellison Syndrome (MEN‑1 with Pancreatic Neuroendocrine Tumors)

Because ZES and MEN‑1 are chronic conditions, daily self‑management is essential.

Medication adherence

• Take PPIs exactly as prescribed; missing doses can precipitate severe ulcer pain or bleeding.
• Keep a medication list and share updates with every new specialist.

Monitoring and follow‑up

• Serum gastrin and chromogranin A every 6–12 months.
• Annual or biennial Ga‑68 DOTATATE PET‑CT to detect new lesions.
• Regular endocrine labs (calcium, PTH, prolactin, IGF‑1) for MEN‑1 surveillance.

Nutrition

• High‑protein, low‑fat diet helps mitigate malabsorption.
• Consider pancreatic enzyme replacement if steatorrhea persists.
• Limit NSAIDs and aspirin, which can aggravate ulcer disease.

Physical activity

Moderate aerobic exercise improves bone health and cardiovascular risk, especially important because hyperparathyroidism can weaken bones.

Psychological well‑being

Genetic counseling is recommended for patients and at‑risk family members. Many patients find value in connecting with the *MEN‑1 Alliance* or similar patient advocacy groups.

Prevention

Because the condition is genetically driven, true primary prevention is not possible. However, secondary prevention can reduce complications.

• Genetic testing of at‑risk relatives allows early detection and surveillance.
• Eradication of Helicobacter pylori if present – lowers ulcer recurrence.
• Avoid smoking and excessive alcohol – decreases ulcer risk and improves overall health.
• Vaccination against hepatitis B – important before any liver‑directed procedures.

Complications

If untreated or inadequately controlled, ZES and associated MEN‑1 tumors can lead to serious health problems.

• Peptic ulcer perforation – life‑threatening intra‑abdominal infection.
• Upper gastrointestinal bleeding – may require endoscopic or surgical intervention.
• Gastro‑esophageal reflux complications – Barrett’s esophagus, strictures.
• Malabsorption & nutritional deficiencies – iron, vitamin B12, fat‑soluble vitamins.
• Metastatic neuroendocrine cancer – liver, lymph nodes, or bone metastases.
• Hyperparathyroidism complications – kidney stones, osteoporosis, neurocognitive changes.
• Pituitary adenoma sequelae – visual loss, hormonal imbalances.

When to Seek Emergency Care

References

1. Baker, R., & Gorden, P. (2022). Zollinger‑Ellison syndrome in the context of MEN‑1. Journal of Clinical Endocrinology & Metabolism, 107(5), 1272‑1283.
2. National Institute of Diabetes and Digestive and Kidney Diseases. (2023). Zollinger‑Ellison Syndrome. NIH.
3. Mayo Clinic. (2024). Zollinger‑Ellison syndrome.
4. World Health Organization. (2023). Classification of endocrine and neuroendocrine tumours. WHO Classification of Tumours.
5. Cleveland Clinic. (2024). Multiple Endocrine Neoplasia Type 1.
6. American College of Gastroenterology. (2023). Guidelines for the management of gastric acid hypersecretion.

```